Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Organon and Co
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Is male or female ≥ 18 years of age in general good health (other than RA)
Has an American College of Rheumatology Rheumatoid Clinical Response Criteria (ACR) Functional Class I, II, or III
Has a diagnosis of RA at least 6 months ago and was at least 16 years of age when diagnosed
Has a history of positive therapeutic benefit with nonsteroidal anti-inflammatory drugs (NSAIDs) and is taking an NSAID on a regular basis and at a therapeutic dose level and is not anticipated to undergo a change during the study
You may not be if
Has a concurrent medical/arthritic disease that could confound or interfere with evaluation of efficacy
Has a history of gastric or biliary surgery (including gastric bypass surgery) or small intestine surgery that causes clinical malabsorption
Has an active peptic (gastric or duodenal) ulcer or history of inflammatory bowel disease
Has a confirmed medical diagnosis of ischemic heart disease, cerebrovascular disease, or peripheral artery occlusive disease
Class II-IV congestive heart failure
Has uncontrolled hypertension (systolic \>160 mm Hg or diastolic \> 90 mm Hg) at Visit 1 or Visit 2
Has a clinical diagnosis of hepatic insufficiency defined as Child-Pugh score ≥5
Has estimated glomerular filtration rate ≤30 mL/min
Has a history of neoplastic disease within 5 years (exceptions: basal cell carcinoma or carcinoma in situ of the cervix)
Is allergic to etoricoxib; history of a significant clinical or laboratory adverse experience associated with etoricoxib; hypersensitivity to aspirin or NSAIDs; or allergy to acetaminophen/paracetamol
Has a personal or family history of an inherited or acquired bleeding disorder
Requires oral corticosteroid therapy in excess of the equivalent of 10 mg daily of prednisone and/or have not been on a stable dose for at least 4 weeks prior to Visit 1 and/or whose dose is not expected to remain stable during the study
Treated with B-cell depleting therapies within the past 6 months or anticipate this treatment during this trial
Is a recreational or illicit drug use, or history within 5 years of drug or alcohol abuse/dependence;
Is morbidly obese (defined as body mass index ≥40 kg/m\^2)
